BCM
NBIX icon

Basso Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Basso Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,100
Closed -$680K – 181
2017
Q3 		$680K Buy
+11,100
New +$586K 0.08% 128

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Basso Capital Management's NBIX Position: Q4 2017 in Review

Basso Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2017, closing a stake of 11,100 shares — an estimated $680K sold.

Basso Capital Management first reported a position in NBIX in Q3 2017 and held it in 1 quarter. The position peaked at $680K in Q3 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q4 2017.

  • Basso Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2017 after selling out during the quarter.
  • Basso Capital Management sold 11,100 Neurocrine Biosciences shares in Q4 2017, an estimated $680K.
  • Basso Capital Management first reported a position in Neurocrine Biosciences in Q3 2017 and held it in 1 quarter.
  • Basso Capital Management's Neurocrine Biosciences position peaked at $680K in Q3 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2017.

Based on Basso Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.